Monday, 24 Feb 2020

PsA/SpA

Date Typesort ascending Title Save
12 Nov 2019 Social RT @_connectedcare: Ixekizumab in nrAXSpa Outcomes met. Another positive trial #ACR19 @rheumnow Abst2729 https://t.co/VVUKSi6sCQ
13 Feb 2020 Social RT @Janetbirdope: Non radiographic ankylosing spondylitis pts are younger, less % males and lower CRP than radiographic AS #RWCS2020 @Rhe…
04 Nov 2017 Social RT @cgytz: Lumbar mobility is impaired first in SpA. Screen with modified Schober and lateral spinal flexion. #rheumedu #ACR17 https://t.co…
07 May 2017 Social Pfizer submitted tofacitinib NDA to FDA for psoriatic arthritis. FDA prev denied the NDA for psoriasis w/ CR letter. https://t.co/1EMk9QsW3V
02 Feb 2017 Social A study of 1305 pts shows Psoriatic Arthritis has a 43% higher risk of diabetes. Risk linked to tender Jts and ESR. https://t.co/XdP3IXnJ3G
30 Apr 2018 Social April meeting of European Medicines Agency, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of new indications for CIMZIA- certolizumab pegol (for plaque psoriasis) and XELJANZ-tofacitinib (for psoriatic arthritis). https://t.co/W4A0AIyZ80
16 Feb 2019 Social Dr Eric Ruderman shows data on the lack of effect with ustrkinumab in biological naive ankylosing spondylitis. #RWCS2019 https://t.co/Wqx7Us1Qrl
13 Nov 2019 Social RT @uptoTate: Risankizumab (RZB), humanized IgG1 monoclonal antibody and selective IL23p19 inhibitor, superior to PBO in PsA. Initial phase…
05 Nov 2017 Social RT @_connectedcare: 12% progression in 2yrs to AS from nrAxSpA #ACR17 @rheumnow https://t.co/QcFR8zzRXF
26 Jul 2015 Social RT@DrPetryna Interesting read. Role of IL23 pathway and Innate Lymphoid Cells in pathogenesis of AS and IBS - http://t.co/EXAuGRvnfz
30 Jul 2015 Social PSOLAR registry Infection risk w/ age, DM, smoking, prior Infx, INFLX, ADA. Low rate w/ Stelara 0.83 & ETN 1.47/100PY http://t.co/OxTbxe2HN9
09 Nov 2017 Social RT @japaoli19: @RheumNow Agree. Only 6% were strong recommendations. Glad they addressed comorbidities but management not necessarily consi…
13 Jun 2018 Social Lindstrom studied their Swedish AS registry and found that While the presence of Uveitis was assoc w/ better TNFi responses; all other comorbidities yielded lesser TNFi responses. #EULAR2018 @RheumNow OP0023 https://t.co/bltRC4khbL
22 Oct 2018 Social RT @japaoli19: Abstract 1631 20% incidence of uveitis in SpA with IBD phenotype having the highest incidence #ACR18 @rheumnow https://t.co…
24 Oct 2019 Social Observational study of the meditteranean diet on 211 Psoriatic Arthritis patients. 27% had MetSyndr. Moderate adherence 66%. Disease activity (DAPSA, HAQ) was inversely correlated with diet adherence. The most active PsA had the lowest adherence https://t.co/2Yf22zEH2o
03 Aug 2017 Social FDA Arthritis Advisory Panel votes 10-1 in favor of approving tofacitinib (Xeljanz) for use in Psoriatic athritis. FDA decision pending.
07 Nov 2017 Social RT @DrPetryna: FUTURE5: Cosentyx clinically&radiofraph superior toPBO. mTSS non-progression 88%Cosentyx vs73% PBO #L17 #acr17 @RheumNow htt…
29 Apr 2016 Social Extensive skin psoriasis is a risk factor for Psoriatic Arthritis - other risk factors nail dz, obesity & smoking https://t.co/NZAqi0RJDB
07 Oct 2016 Social Am I wrong?Otezla warnings overstate risk of depression % wt loss; yet understate diarrhea 9% & D/C for diarrhea <2% https://t.co/UwFi8b6txr
17 Dec 2017 Social FDA approves Xeljanz (tofacitinib) for use in adults with psoriatic arthritis, alone or in combo w/ MTX/DMARDs. But warns agains combining with biologics, cyclosporine or azathioprine as these have not been studied. https://t.co/ffsAfiaU70